SELLAS Life Sciences Group, Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company specializing in the development of novel therapeutics for a broad range of cancer indications. The company's main product candidates include galinpepimut-S (GPS), a peptide immunotherapy targeting the Wilms Tumor 1 (WT1) protein, which is implicated in various hematologic malignancies and solid tumors, and SLS009 (tambiciclib), a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor with potential applications in acute myeloid leukemia (AML) and other myeloid diseases. SELLAS develops these therapies with a focus on oncology and immunotherapy, leveraging strategic collaborations with institutions like Memorial Sloan Kettering Cancer Center for licensing and development purposes. The company operates primarily in the United States with extensible global licensing arrangements. Founded in 2012 and headquartered in New York City, SELLAS has recently advanced its clinical pipeline with significant clinical trial progress, including continued development of SLS009 with expected trial enrollment in early 2026. The company executed a $31 million warrant exercise with an institutional investor in late 2025, bolstering its financial position to support ongoing operations. SELLAS also partnered with WEP Clinical to launch an Expanded Access Program for galinpepimut-S to support patients during the ongoing pivotal REGAL Phase 3 clinical trial in AML. These operational moves reflect the company’s strategic emphasis on late-stage clinical development and commercialization readiness in oncology therapeutics. SELLAS Life Sciences engages in multiple collaborations and licenses, including an exclusive global license from Memorial Sloan Kettering Cancer Center for its WT1-targeting cancer immunotherapy. The company is also advancing its CDK9 inhibitor licensed from GenFleet Therapeutics for global markets outside Greater China. Its products are positioned for use as monotherapy or in combination with other therapies for a variety of hematologic cancers and solid tumors, targeting patient populations with high unmet medical needs. The firm’s pipeline development is supported by strong clinical data signals and regulatory incentives such as the FDA Rare Pediatric Disease Designation for pediatric AML treatment. In summary, SELLAS Life Sciences Group develops innovative immunotherapeutic and small molecule oncology drugs, focusing on WT1-targeted therapy and CDK9 inhibition. Its recent key developments include clinical trial progress for SLS009, expanded access for GPS, a significant capital raise through warrant exercises, and ongoing scientific and commercial partnerships aimed at advancing late-stage cancer drug candidates toward market approval and commercialization. This description reflects SELLAS Life Sciences Group’s comprehensive focus on oncology biopharmaceuticals, recent clinical advancements, collaborations, and financial strengthening as of late 2025.
Company News
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 11.2% – Here’s What Happened
SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Study
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
Power Metallic Defines High-Grade Maiden Resource at Lion Averaging ~3.9% CuEq, with >85% Indicated and Significant Expansion Potential
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
This One Data Readout Could Make Or Break Sellas Life Sciences Group
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst